Atherosclerosis Clinical Trials 2023

What are the top hospitals conducting atherosclerosis research?

In the battle against atherosclerosis, several top hospitals across different locations are leading the charge in clinical trials aimed at understanding and combating this condition. Massachusetts General Hospital, situated in Boston, stands out with five ongoing trials focused on atherosclerosis. With a history of 19 trials dedicated to this artery-clogging disease, their commitment dates back to their first recorded trial in 2000. Meanwhile, on the West Coast, Westside Medical Associates of Los Angeles is making significant contributions as well. This Beverly Hills-based institution has four active atherosclerosis trials underway and has conducted five previous studies since initiating its first trial in 2016.

Moreover, Excel Medical Clinical Trials based in Boca Raton demonstrates its dedication through four ongoing clinical investigations into atherosclerosis since recording its inaugural trial on this subject matter as recently as 2021. Similarly enthusiastic about advancing knowledge and treatment options for those suffering from this ailment is Clinical Trials Research located in Lincoln; they contribute actively by conducting three current investigations while boasting three accomplished experiments initiated when they administered their initial record-trialing process regarding Atherosclerosis just last year -in2022.

Lastly,the efforts of West Broadway Clinic located specifically within Council Bluffs region also constitutes notable contribution towards broadening insights amidst fight against aforementioned ailment ;they undertake similar magnitude of task being involved with research pertaining towards three active clinical examinations targeting Atherosclerotic territories.These relatively smaller-scale institutions hold equal importance given that every step taken toward comprehending and managing Atherosclerosis ultimately offers hope for millions who suffer from it worldwide.

These leading healthcare facilities not only provide patients with access to cutting-edge treatments but also serve as vital sources for advancements that can transform lives affected by atherosclerosis. By joining forces through these impactful clinical trials and dedicating resources to innovative research initiatives we come closer every day towards unraveling mysteries behind such diseases which pave way eventual eradication thereof

Which are the best cities for atherosclerosis clinical trials?

When it comes to atherosclerosis clinical trials, several cities in the United States are at the forefront of research. Boston, Massachusetts stands out with 13 active trials exploring treatments such as Olpasiran, Stress Reduction, and IVUS guided PCI. Miami, Florida follows closely behind with 10 ongoing studies focused on interventions like Olezarsen, Obicetrapib, and Metformin XR. New york City also plays a significant role in atherosclerosis research with 9 active trials investigating treatments like IVUS guided PCI and RANGER™ Paclitaxel Coated Balloon. These three cities offer individuals affected by atherosclerosis access to cutting-edge clinical trials that hold promise for advancements in care and improved outcomes.

Which are the top treatments for atherosclerosis being explored in clinical trials?

Atherosclerosis, a condition characterized by the buildup of plaque in the arteries, is being met with innovative treatments in clinical trials. Prominent among these are stress reduction techniques, which have shown promise in two active and two all-time atherosclerosis trials since 2018. Additionally, olezarsen has caught attention for its potential benefits and is currently under investigation in two ongoing trials after first being listed in 2022. Inclisiran has also emerged as an intriguing candidate, with six all-time atherosclerosis trials and two active studies underway following its introduction to the medical scene in 2017. Finally, obicetrapib rounds out this list of top contenders with its inclusion in two current investigations since it was first listed just last year.

What are the most recent clinical trials for atherosclerosis?

Exciting advancements in the field of atherosclerosis research bring hope for improved treatments and outcomes. Recent clinical trials have investigated several interventions targeting this condition. One such trial focuses on tirzepatide, aiming to assess its effectiveness in managing atherosclerosis. Another promising study explores the potential benefits of semaglutide as a treatment option for this disease. Additionally, metformin XR has been evaluated to determine its impact on atherosclerosis progression. Lastly, inclisiran sodium 300mg is being investigated in Phase 3 trials for its potential role in combating this condition. These ongoing studies hold promise for advancing our understanding and management of atherosclerosis, offering new possibilities for patients' well-being.

What atherosclerosis clinical trials were recently completed?

Recently completed clinical trials have made significant strides in the field of atherosclerosis research. In August 2021, Novo Nordisk A/S concluded a trial investigating the potential of NNC0385-0434 A 15 mg as a treatment option. Mayo Clinic's trial exploring Granulocyte Colony-Stimulating Factor (G-CSF) reached completion in June 2018, shedding light on its effectiveness against this condition. Furthermore, in April 2017, Novartis Pharmaceuticals wrapped up their study evaluating Inclisiran. These trials signify important progress and offer hope for improved interventions to combat atherosclerosis and its associated complications.